



Oregon PDAB Quarterly, Issue 14, April 24, 2026, pdab@dcbs.oregon.gov

PDAB will host online, in-person community forums

We invite you to attend a community forum sponsored by the Oregon Prescription Drug Affordability Board (PDAB). The in-person forums will be held May 5 at the Salem Library, May 6 at the Redmond Library, May 12 at the Asian Health & Service Center in Portland, and May 18 at the Beaverton Library. We also have online forums on April 28, May 11, May 13, and the online board meeting, May 20.

The board wants to hear from patients, caregivers, and other Oregonians about the cost of their medications and how it affects their lives. All forums will have similar content, so choose the best option for your schedule. We would love to have you join us!

The online meetings will be held on [ZoomGov](https://zoom.us). Join any meeting at the scheduled time at zoomgov.com/join. Enter the meeting ID and passcode.

- [Click here for a PDAB community forum flyer in English](#)
- [Descargue un volante del foro comunitario en español](#)

The May 13 meeting will be in Spanish. The April 28, May 11, and May 20 meetings will have Spanish interpretation offered in a Zoom channel. American Sign Language interpretation will be provided at the May 20 meeting and upon request at the other meetings.

The May 20 meeting is a board meeting with an extended public comment period. If you would like to speak during the May 20 board meeting, please [fill out the public comment form on the PDAB website](#).

Please come to a community forum and share your story about prescription drug costs with board members. Your feedback will help inform PDAB's review process. We look forward to seeing you!

In-person forums

Salem – Tuesday, May 5, 5 to 6:30 p.m.
Salem Public Library
585 Liberty St. SE
Salem

Redmond – Wednesday, May 6, 5 to 6:30 p.m.
Redmond Public Library
827 SW Deschutes Ave.
Redmond

Portland – Tuesday, May 12, 6 to 7:30 p.m.
Asian Health & Service Center
9035 SE Foster Road
Portland

Beaverton – Monday, May 18, 5 to 6:30 p.m.
Beaverton City Library
12375 SW Fifth St.
Beaverton



Oregon Prescription Drug
Affordability Board

Online forums

Join any ZoomGov meeting at the scheduled time at zoomgov.com/join
Enter the meeting ID and passcode

Passcode: OregonPDAB
Dial in by phone: 669-254-5252

Tuesday, April 28, 7 to 8:30 p.m.
Join ZoomGov Meeting
Meeting ID: 161 635 9753

Monday, May 11, noon to 1:30 p.m.
Join ZoomGov Meeting
Meeting ID: 160 556 2737

Wednesday, May 13, 6:30 to 8:30 p.m.
Join ZoomGov Meeting
Meeting ID: 160 948 4958
[En Español](#)

PDAB board meeting:
Wednesday, May 20, 8 a.m. to noon
Join ZoomGov Meeting
Meeting ID: 161 233 0328

Board selects prescription drugs, insulin for 2026 review

Oregon PDAB selected a subset list of prescription drugs and insulin products for affordability review in 2026 using the criteria in Oregon Administrative Rules, [OAR 925-200-0010](#). The board voted on the list during the March 18 meeting. The board will review Jardiance, Mounjaro, Ozempic, and Humulin R U-500 (concentrated and Kwikpen) during the June meeting, Keytruda, Verzenio, and Xeljanz in July, and Ocrevus, Skyrizi, Tremfya, and Xolair in August. See the table below for the drugs' main treatment. In September and October, the board will review all drugs and discuss recommendations for the annual report. The board will complete its report to the Oregon Legislature in December.

The PDAB drug review process is set forth in [OAR 925-200-0020](#), which outlines the criteria and factors the board uses to determine how drugs affect the health care system and patient out-of-pocket costs. As part of the process, the board analyzes data reported by state health plans and the All Payer All Claims (APAC) database. The board also gathers voluntary information from manufacturers, medical experts, clinics, patients, caregivers, and other contributors. The board then presents its findings and policy recommendations to the Oregon Legislature.

PDAB prescription drug review schedule for 2026

PDAB meeting date	Prescription drug	Main treatment
June 17	Jardiance	Type 2 diabetes
June 17	Mounjaro	Type 2 diabetes
June 17	Ozempic	Type 2 diabetes
June 17	Humulin R U-500 (concentrated and KwikPen)	Improve blood sugar control in adults and children with diabetes (Type 1 and Type 2) who require more than 200 units of insulin per day
July 15	Keytruda*	Cancer
July 15	Verzenio	Cancer
July 15	Xeljanz	Several autoimmune and inflammatory conditions
Aug. 19	Ocrevus	Multiple sclerosis (MS)
Aug. 19	Skyrizi*	Immune-mediated inflammatory conditions
Aug. 19	Tremfya	Plaque psoriasis
Aug. 19	Xolair	Allergic and inflammatory conditions in both adults and children
Sept. 16 and Oct. 21		The board will review all drugs and discuss recommendations for the annual report

*Indicates a designation of a drug for rare diseases or conditions

Oregon PDAB executive director update



Oregon PDAB accomplished much in the first quarter of 2026. In March, the board published its first [drug review report for the Oregon Legislature](#). The report focused on the board's selection of four drugs that may create affordability challenges for Oregonians: Cosentyx, Trulicity, Vraylar, and Lantus SoloStar.

Also in March, the board selected a [subset list of 12 drugs for review in 2026](#). To prepare for the upcoming review, staff sent a data call to Oregon health insurance companies, requesting information about medications on the subset list. The board will use the aggregated information to help inform its decisions about affordability challenges in the 2026 drug review. Once the data call is complete, our team will create an online [data dashboard](#) on the PDAB website for the 2026 review process. The data dashboard is a tool board members may use as they conduct affordability reviews.

While the board awaits completion of the data call, it used the April meeting to learn more about prescription drug programs offered by the State of Oregon and received an overview of our proposed data analysis methodology from staff. At the May meeting, board members are extending the public comment portion of the agenda and are inviting people to share comments about the [drugs under review](#). If you would like to speak to the board during the May meeting, please fill out the [public comment form on the PDAB website](#) to sign up.


You can also participate is by completing a feedback form about the [prescription drugs under review in 2026](#). The board developed online survey-style forms to gather input from stakeholders and to help inform the drug review process. The feedback forms are available for patients, caregivers, and advocacy groups; people with scientific or medical expertise; safety net providers and clinics; manufacturers; pharmacy benefit managers; and health insurance companies. You can [find the form that applies to you on the PDAB website](#). The forms will remain open until late August.

Finally, the Oregon Legislature passed [House Bill 4040](#), which affects PDAB's work. Section 35 of the bill updates [ORS 646A.694](#) by removing the requirement that the board *must* identify at least one insulin product each year in their affordability review. Under the language of HB 4040, the board may identify insulin products that may create affordability challenges but is not required to do so if the insulin does not meet the review criteria under [OAR 925-200-0020](#). PDAB staff will continue to provide the board with a full list of insulin products used in Oregon for consideration each year, ensuring the board has the information needed to select insulin products for affordability reviews. HB 4040 takes effect immediately, and the updated statutory language will apply to the board's 2026 affordability reviews.

PDAB wants to hear from patients, other Oregonians

We invite you to submit a feedback form about the drugs under review

PDAB is seeking input from patients, caregivers, and other Oregonians about the cost of prescription medications and how those costs affect daily lives. The board invites patients, caregivers, advocacy groups, medical professionals, scientific professionals, manufacturers, safety net clinics, pharmacy benefit managers, and health insurers to submit a feedback form for the prescription drugs currently under review.



PDAB will review the following medications to evaluate their affordability and their effect on Oregonians and the state's health care system: [Jardiance](#), [Mounjaro](#), [Ozempic](#), [Humulin R U-500](#), [Keytruda](#), [Verzenio](#), [Xeljanz](#), [Ocrevus](#), [Skyrizi](#), [Tremfya](#), and [Xolair](#).

If any of these prescription drugs have affected your health, finances, or the communities you serve, we encourage you to share your experiences with the board. Your feedback will help inform PDAB's review process.

You can [find the feedback forms on the PDAB website](#). You may also use the direct links or QR code below by selecting the applicable form, completing the questions, and submitting the form. There are category descriptions with each link. The patients, caregivers, and advocacy groups form is also available in Spanish. Forms will remain open until late August. Thank you, in advance, for your participation.



[Patients, caregivers, and advocacy groups](#)

For individuals who have been prescribed a medication on the review list, as well as their caregivers or family members. Advocacy groups representing patients or caregivers may also choose this form.



[Solicitud de información: pacientes, cuidadores de pacientes, grupos de representación](#)

Para las personas a las que se les ha recetado un medicamento de la lista de revisión, así como para sus cuidadores o familiares. Los grupos de defensa que representan a pacientes o cuidadores también pueden elegir esta forma.

Continued on Page 5

Continued from Page 4



[Individuals with scientific or medical training](#)

For medical providers, doctors, nurses, professors, researchers, pharmacists, representatives of medical clinics and hospitals, and others with a background and training in medicine or science.



[Safety net provider](#)

For 340B clinics, federally qualified health centers serving Oregon communities, and coordinated care organizations serving Oregon Health Plan members.



[Manufacturer](#)

For companies that manufacture prescription drugs and trade associations representing manufacturers.



[Pharmacy benefit manager](#)

For pharmacy benefit managers – third-party administrators that manage prescription drug programs for health plans.




[Health plan insurer](#)

For companies that provide health insurance to Oregonians.

Sign up to speak at the May 20 online board meeting

The board invites the public to speak at the May 20 board meeting about [the drugs under review in 2026](#). The board will have an extended public comment time to hear from patients, advocacy groups, manufacturers, medical professionals, pharmacy experts, researchers, health clinic representatives, health insurance companies, pharmacy benefit managers, and others. [To sign up, fill out and submit the public comment form on the PDAB website at least 24 hours before the meeting](#). You may also submit letters through the public comment form on the website at least 48 hours before the meeting. Written comments will be publicly posted on the website and shared with the board. If you have questions, please email pdab@dcbs.oregon.gov or call 971-374-3724.



PDAB submits 2025 drug review report to Oregon Legislature

In March, the Oregon PDAB delivered its first drug review report to the Oregon Legislature. The [2025 drug review report](#) discusses the board’s identification of drugs that may create affordability challenges: Cosentyx, Trulicity, Vraylar, and Lantus SoloStar. The report includes two recommendations for improving affordability for patients – a patient out-of-pocket cap and a point-of-sale rebate pass through. A policy memo attached to the report provides background on the recommendations.

The board’s vote in January on the four medications was the culmination of six months of review of a subset list of 23 prescription drugs and insulin products, conducted from July through December of 2025.

Each year, the board conducts affordability reviews to identify up to nine prescription drugs that may create affordability challenges for health care systems or result in high out-of-pocket costs for patients in Oregon, as required by [ORS 646A.694](#). The board also reviews insulin products and may include them in the annual report.

- Click to find the [2025 drug report](#) on the PDAB website.
- Click to find past board reports on the [Legislative reports page](#).



Cherry blossoms at the Oregon Capitol Mall, March 2026. Photo by Stephen Kooyman.

Oregon PDAB meeting schedule in 2026

PDAB meetings are open to the public and held online on [ZoomGov](#) the third Wednesday of the month. Meetings start at 8 a.m. unless the board adjusts the time posted in the agenda. Find agendas, meeting materials, minutes, videos, and public comments on the [board calendar and materials page of the PDAB website](#).

[To receive agenda and meeting materials notices, click here to sign up for PDAB notices.](#)

If you would like to sign up to speak during the public comment portion of a board meeting, fill out the [public comment form on the PDAB website](#) at least 24 hours before the meeting. Here is the schedule of meetings remaining in 2026. To register for the board meeting, click on the meeting date.

- [Wednesday, May 20, from 8 a.m. to noon](#)
- [Wednesday, July 17, from 8 a.m. to noon](#)
- [Wednesday, July 15, from 8 a.m. to noon](#)
- [Wednesday, Aug. 19, from 8 a.m. to noon](#)
- [Wednesday, Sept. 16, from 8 a.m. to noon](#)
- [Wednesday, Oct. 21, from 8 a.m. to noon](#)
- [Wednesday, Nov. 18, from 8 a.m. to noon](#)
- [Wednesday, Dec. 16, from 8 a.m. to noon](#)

PDAB, DPT website have updates, format changes

The Oregon PDAB and Oregon Drug Price Transparency (DPT) Program have been reviewing their websites and reformatting documents to make them easier to read for people who use assistive technology, such as a screen reader. Staff members have reorganized files and created archive folders. If you have any difficulties finding website content, please email PDAB at pdab@dcbs.oregon.gov or DPT at rx.prices@dcbs.oregon.gov so we can help.



Lanterns hanging among the cherry blossoms at the Oregon Capitol Mall, March 2026. Photo by Stephen Kooyman.